Goldman Sachs analyst Robert Jones continues to see Icon PLC (NASDAQ: ICLR) shares undervalued as he added the pharmaceutical company to America’s Conviction List. Jones has a Buy rating on the stock with a revised price target of $117.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to ICON (ICLR):